Abbott Laboratories
ABT
$135.08
-$2.63-1.91%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.59% | 3.15% | 1.24% | -2.84% | -8.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.59% | 3.15% | 1.24% | -2.84% | -8.12% |
| Cost of Revenue | 4.05% | 1.23% | 0.58% | -2.10% | -6.10% |
| Gross Profit | 5.03% | 4.71% | 1.78% | -3.43% | -9.69% |
| SG&A Expenses | 6.97% | 3.01% | 1.24% | -0.86% | -2.97% |
| Depreciation & Amortization | -4.48% | -4.39% | -3.18% | -2.26% | -2.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.76% | 1.45% | 0.15% | -1.70% | -4.78% |
| Operating Income | 3.82% | 11.40% | 6.50% | -7.83% | -20.77% |
| Income Before Tax | 5.24% | 9.52% | 3.71% | -6.49% | -19.77% |
| Income Tax Expenses | -778.96% | -1.56% | -14.62% | -23.57% | -31.46% |
| Earnings from Continuing Operations | 134.18% | 11.72% | 7.67% | -3.00% | -17.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 134.18% | 11.72% | 7.67% | -3.00% | -17.45% |
| EBIT | 3.82% | 11.40% | 6.50% | -7.83% | -20.77% |
| EBITDA | 2.40% | 7.60% | 4.62% | -5.58% | -15.48% |
| EPS Basic | 134.13% | 11.77% | 7.99% | -2.70% | -16.88% |
| Normalized Basic EPS | 3.46% | 10.82% | 5.55% | -7.25% | -20.07% |
| EPS Diluted | 134.55% | 11.93% | 8.21% | -2.38% | -16.58% |
| Normalized Diluted EPS | 3.49% | 10.86% | 5.61% | -7.04% | -19.85% |
| Average Basic Shares Outstanding | -0.03% | -0.08% | -0.30% | -0.37% | -0.63% |
| Average Diluted Shares Outstanding | -0.05% | -0.11% | -0.32% | -0.55% | -0.84% |
| Dividend Per Share | 7.69% | 7.84% | 8.00% | 8.16% | 8.33% |
| Payout Ratio | -0.54% | -0.03% | 0.00% | 0.11% | 0.30% |
